ANTI-PAR-4 化學(xué)特性,用途語(yǔ),生産方法
使用
All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project
(www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry.
The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these
protocols and other useful information about Prestige Antibodies and the HPA, visit .
一般的な説明
Coagulation factor II (thrombin) receptor-like 3 (F2RL3) is a member of the large family of 7-transmembrane-region receptors that couple to guanosine-nucleotide-binding proteins. F2RL3 is also a member of the protease-activated receptor family. F2RL3 is activated by proteolytic cleavage of its extracellular amino terminus. The new amino terminus functions as a tethered ligand and activates the receptor. F2RL3 is activated by thrombin and trypsin. (provided by RefSeq)
Biochem/physiol Actions
PRKC apoptosis WT1 regulator protein (PAWR) induces the apoptosis of prostate cancer cells and causes tumor regression. It inhibits the nuclear factor κ-B (NF-κB) activity and also the cell membrane trafficking of Fas (a cell surface death receptor) and Fas ligand (FasL). This leads to the activation of the Fas-Fas-associated death domain-caspase-8 pro-death pathway. The deletion in the gene encoding PAWR leads to pancreatic cancers and male germ cell tumors. PAWR takes part in neuronal degeneration and cholinergic signaling in Alzheimer′s disease. It interacts with CHT1 (a choline transporter) and regulates choline uptake. It functions as a negative regulator of the choline uptake activity by reducing the CHT1 incorporation on the cell surface. WT1 (a transcriptional regulator) has a transcriptional activation domain which can only be activated by specifically interacting with PAWR.
ANTI-PAR-4 上流と下流の製品情報(bào)
原材料
準(zhǔn)備製品